Pharma giant GSK has unveiled plans for a new 300,000-square-foot global research-and-development centre on the Cambridge Biomedical Campus, committing £400 million over three years and setting the stage for one of the UK’s largest life-sciences relocations this decade. An RNS filing to the London Stock Exchange confirms that more than 1,000 scientists currently based at Stevenage will move to Cambridge in phases up to 2029, while additional staff will transfer to upgraded laboratories in Ware, Hertfordshire. The investment further embeds GSK in Britain’s “Golden Triangle” of Oxford-Cambridge-London bio-innovation, giving researchers closer proximity to clinical partners such as Addenbrooke’s Hospital and the University of Cambridge. Chief Executive Luke Miels said the move will “accelerate science that matters most for GSK’s next wave of medicines,” particularly in oncology, vaccines and HIV. From a global-mobility perspective, the project will demand complex group moves, short-term commuter arrangements and fresh Certificates of Sponsorship for non-UK talent. GSK’s HR team is expected to negotiate relocation packages, schooling support and spousal-work permission under the Skilled Worker and Global Talent visa routes. The shift may also create knock-on demand for local housing and international schools around Cambridge, already one of Britain’s tightest rental markets. Cambridge local authorities have welcomed the announcement but called for expedited transport links to absorb the influx. Mobility providers supplying temporary accommodation, destination services and tax briefings should prepare for a multi-year pipeline of assignments linked to the build-out and eventual decommissioning of the Stevenage site.
